Papers - YAMAMOTO Hayato
-
Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study
Oishi T, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Tanaka R, Ishii N, Miura H, Tanaka T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Sato S, Ohyama C.
Multicenter Study 2023.2
-
Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study
Ozaki Y, Narita T, Hatakeyama S, Tanaka T, Togashi K, Hamaya T, Ozaki K, Ishi N, Oishi T, Tokui N, Mikami J, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Transl Androl Urol . 2023.2
-
Can Erectile Dysfunction Severity Predict Major Adverse Cardiovascular Events in Men Undergoing Dialysis? A Prospective Cohort Study
Fujita N, Momota M, Ozaki Y, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
World J Mens Health 2023.1
-
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
Ozaki K, Hatakeyama S, Narita S, Hata K, Yanagisawa T, Tanaka T, Togashi K, Hamaya T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Kimura T, Habuchi T, Ohyama C.
World J Urol. 2023.1
-
Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction
Miura H, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Tanaka R, Noro D, Tokui N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Urol Oncol 2022.12
-
Relationships of low-grade systemic inflammation and nutritional status with erectile dysfunction severity in men on dialysis
Fujita N, Hatakeyama S, Momota M, Hamaya T, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
Andrology 2022.11
-
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
2022.10
-
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
Sci Rep . 2022.8
-
Association between Aortic Calcification Burden and the Severity of Erectile Dysfunction in Men Undergoing Dialysis: A Cross-Sectional Study
Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
World J Mens Health . 2022.4
-
Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.
Oishi T, Hatakeyama S, Tabata R, Fujimori D, Fukuda M, Shinozaki T, Ishii N, Iwamura H, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Sato S, Ohyama C.
Sci Rep. 2022.3
-
Renal metastasis of ovarian granulosa cell tumor
Kyo Togashi, Tohru Yoneyama, Mihoko Sutoh Yoneyama, Hayato Yamamoto, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Masayuki Futagami, Chikara Ohyama
IJU Case Rep 2022.3
-
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C.
Urol Oncol. 2021.12
-
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C.
Urol Oncol 2021.12
-
Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries
Konishi S, Narita T, Hatakeyama S, Yoneyama T, Yoneyama MS, Tobisawa Y, Noro D, Sato T, Togashi K, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Sci Rep . 2021.11
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era
Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N.
Int J Clin Oncol . 2021.10
-
Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T, Hatakeyama S, Tanaka T, Kubota Y, Togashi K, Hosogoe S, Fujita N, Kusaka A, Tokui N, Okamoto T, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Ohyama C.
BJU Int. 2021.10
-
Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years
Togashi K, Hatakeyama S, Okamoto T, Kojima Y, Iwamura H, Fujita N, Narita T, Hamano I, Hamaya T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Urol Oncol. 2021.10
-
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer
Kubota Y, Hatakeyama S, Yoneyama T, Yoneyama MS, Hamano I, Konishi S, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
World J Urol . 2021.9
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N
International journal of clinical oncology 2021.6
-
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer
Hirotaka Horiguchi, Ohyama Chikara
Urologic oncology 2021.4